Kissei Pharmaceutical Co., Ltd. provided consolidated earnings guidance for year ending March 2023. For the period, the company expected net sales of JPY 68,500 million, operating profit of JPY 500 million, profit attributable to owners of parent of JPY 10,800 million, Basic earnings per share of JPY 234.19 per basic share.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3,180 JPY | -0.16% | +0.95% | +2.91% |
Jun. 10 | Kissei Pharmaceutical Licenses Linzagolix to JW Pharmaceutical for Korean Market | MT |
Jun. 10 | Kissei Pharmaceutical Co., Ltd. Enters into License Agreement with Jw Pharmaceutical Corporation | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.91% | 892M | |
+17.38% | 78.98B | |
+13.06% | 8.89B | |
+37.14% | 4.29B | |
-23.41% | 4.36B | |
+9.88% | 4.1B | |
+7.00% | 2.16B | |
-28.40% | 2.13B | |
+10.83% | 2.01B | |
-44.01% | 1.75B |
- Stock Market
- Equities
- 4547 Stock
- News Kissei Pharmaceutical Co., Ltd.
- Kissei Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for Year Ending March 2023